GlassScriptPhysician profile
Michael R Rollins
NPI 1275798118
$857.57
in general payments reported to CMS, 2019-2025
13 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $18.53 · 2021: $145 · 2022: $46.72 · 2023: $165 · 2024: $143 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175.14 | 2023-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $147.97 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $127.15 | 2021 | |
| Horizon Therapeutics Plc | $91.81 | 2023 | Uplizna, Tepezza |
| Tarsus Pharmaceuticals, INC. | $67.02 | 2025 | Xdemvy |
| Alcon Vision LLC | $62.55 | 2023-2025 | Rocklatan, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $58.15 | 2022-2025 | Xiidra, Miebo |
| Genentech USA, INC. | $33.82 | 2024 | Vabysmo |
| Rxsight INC | $23.52 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Glaukos Corporation | $22.51 | 2024 | Idose |
| Novartis Pharmaceuticals Corporation | $18.07 | 2021 | |
| Thea Pharma INC. | $17.55 | 2024 | Iyuzeh |
| Mallinckrodt Enterprises LLC | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rollins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.